Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.
Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.
Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.
Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.
Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.
Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.
Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.
Bristol Myers Squibb (NYSE: BMY) received full Marketing Authorization from the European Commission for Onureg (azacitidine tablets) as a maintenance therapy for adults with acute myeloid leukemia (AML) in complete remission. Onureg becomes the first once-daily oral maintenance therapy to showcase significant survival benefits across various AML subtypes. The approval follows the QUAZAR AML-001 Phase 3 clinical trial, which reported a median overall survival of 24.7 months for patients on Onureg compared to 14.8 months on placebo. The treatment aims to address the unmet needs for AML patients not eligible for stem cell transplantation.
Bristol-Myers Squibb (NYSE: BMY) and Eisai Co., Ltd. have announced a collaboration for the co-development and commercialization of MORAb-202, an antibody drug conjugate targeting advanced solid tumors. Eisai will conduct studies in Japan and the U.S., moving toward registrational stages next year. Bristol-Myers Squibb will invest $650 million, including $200 million for R&D, and up to $2.45 billion in potential milestones. Both companies will share profits and costs in specified territories, with Bristol-Myers Squibb handling regions outside these areas.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.49 per share on its common stock, payable on August 2, 2021, with a record date of July 2, 2021. Additionally, a $0.50 dividend on its convertible preferred stock will be paid on September 1, 2021, to stockholders on record by August 10, 2021. The company continues its commitment to returning value to its shareholders.
Bristol Myers Squibb (BMY) and Acceleron Pharma (XLRN) presented promising results from the Phase 2 BEYOND study on Reblozyl® (luspatercept-aamt) for adult patients with non-transfusion dependent beta thalassemia at the EHA 2021 Virtual Congress. 77.7% of patients treated with Reblozyl showed a hemoglobin increase of ≥1.0 g/dL, compared to 0% in the placebo group. The study highlights Reblozyl's potential in improving the quality of life for patients, addressing a significant unmet medical need. The study involved 145 patients over a 48-week treatment period, showing higher efficacy than placebo.
Bristol Myers Squibb (NYSE: BMY) and GRYT Health launched the 'Advocacy Exchange', enhancing the existing COVID Advocacy Exchange to better support patient advocacy organizations. This virtual platform is designed to foster collaboration among advocacy organizations, patients, and industry leaders, providing 24/7 access to educational resources and a searchable resource library. The initiative aims to address health disparities and improve patient experiences through ongoing dialogue and the sharing of best practices.
Bristol Myers Squibb (NYSE:BMY) will release its second quarter 2021 financial results on July 28, 2021, at 8 a.m. ET. Executives will discuss the results during a conference call open to investors and the public. Interested parties can access the live webcast at investor.bms.com or by dialing 888-204-4368 (U.S.) and +1 313-209-4906 (international) using confirmation code 1720109. A replay will be available from 11:30 a.m. ET on July 28 until 11:30 a.m. ET on August 11, 2021.
Bristol Myers Squibb (NYSE: BMY) announced promising topline results from the TRANSFORM Phase 3 study, evaluating Breyanzi (lisocabtagene maraleucel) as a second-line treatment for adults with relapsed or refractory large B-cell lymphoma (LBCL). The trial achieved its primary endpoint, showing significant improvement in event-free survival compared to standard salvage therapy followed by high-dose chemotherapy. Safety outcomes were consistent with previous data, revealing no new concerns. This marks a pivotal moment as Breyanzi demonstrates potential to replace aggressive treatment regimens, impacting the treatment landscape for LBCL.
Bristol Myers Squibb (NYSE: BMY) is set to participate in the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference, scheduled for June 10, 2021, at 9:40 a.m. ET. Key executives, including Chris Boerner, Ph.D., and Samit Hirawat, M.D., will engage in a fireside chat discussing the company's strategic initiatives. A live webcast will be available for investors and the public at investor.bms.com, with an archived version accessible later that day.
Bristol Myers Squibb (NYSE: BMY) reported significant findings from its Phase 3 CheckMate -648 trial for Opdivo combinations in treating advanced esophageal squamous cell carcinoma. Opdivo plus chemotherapy showed a median overall survival (OS) of 15.4 months versus 9.1 months for chemotherapy alone, while Opdivo plus Yervoy resulted in 13.7 months median OS. However, Opdivo plus Yervoy did not achieve its primary endpoint for progression-free survival (PFS). The trial highlights the potential for these combinations to improve treatment outcomes in patients with high PD-L1 expression.
Bristol Myers Squibb (BMY) announced that the European Commission has approved the use of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
This approval follows the positive results from the CheckMate -743 trial, which demonstrated a significant improvement in overall survival compared to standard chemotherapy. The combination showed a 26% reduction in the risk of death, with an overall survival rate at two years of 41% versus 27% for chemotherapy.
FAQ
What is the current stock price of Bristol-Myers Squibb Co. (BMY)?
What is the market cap of Bristol-Myers Squibb Co. (BMY)?
What is Bristol-Myers Squibb's core business?
Where is Bristol-Myers Squibb headquartered?
What was Bristol-Myers Squibb's revenue for fiscal 2022?
What is a significant focus area for Bristol-Myers Squibb?
How much of Bristol-Myers Squibb's total sales come from the U.S. market?
What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?
What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?
What is SpliceCore®?
When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?
What is Bristol-Myers Squibb's mission?
